Physician

Nitin Relia, M.D

According to 2025 Medicare claims, Nitin Relia, M.D (NPI: 1952531857) practices nephrology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is CUMBERLAND NEPHROLOGY ASSOCIATES (NPI: 1710956370; TIN: 223586136) and primary practice location at 08360-6516. Relia is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Relia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 546 traditional Medicare patients, billed 3,255 HCPCS/CPT codes, and received $290,173 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,157 prescription claims across 242 beneficiaries totaling $198,721 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2020 DME data shows 40 claims. Open Payments data shows 45 records totaling $838. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $72,409 and ending at $198,721. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	672	4,181	$303,071
2016	761	5,948	$374,757
2017	766	5,413	$311,496
2018	756	5,248	$338,546
2019	647	4,102	$301,963
2020	548	2,815	$240,817
2021	578	3,486	$320,551
2022	530	3,225	$322,978
2023	520	3,509	$342,545
2024	546	3,255	$290,173

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	189	930	$72,409
2016	204	1,467	$249,609
2017	213	1,398	$250,318
2018	215	1,375	$158,847
2019	216	1,303	$177,467
2020	208	1,327	$173,956
2021	213	1,245	$139,989
2022	202	966	$104,166
2023	204	990	$133,322
2024	242	1,157	$198,721

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	24	$753
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	27	$1,010
2020	N/R	40	$2,010
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	193	220	$136
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	177	267	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	131	180	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	226	749	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	167	287	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	50	3,780	$66,614
Jardiance	Empagliflozin	14	1,260	$24,035
Rayaldee	Calcifediol	13	390	$16,795
Sevelamer Carbonate	Sevelamer Carbonate	15	1,260	$4,816
Cinacalcet Hcl	Cinacalcet Hcl	14	1,020	$3,256

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	45	$838	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nitin Relia, M.D?

Tedicare shows public-source Medicare data for Nitin Relia, M.D (NPI 1952531857), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nitin Relia, M.D have ACO affiliation data?

Nitin Relia, M.D is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Nitin Relia, M.D?

Nitin Relia, M.D is linked to CUMBERLAND NEPHROLOGY ASSOCIATES (billing NPI 1710956370) in the available physician profile data.

Does Nitin Relia, M.D have Open Payments data?

Nitin Relia, M.D has 45 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.